{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:26:45Z","timestamp":1792520805794,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clnesp.2026.103430","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:45:48Z","timestamp":1782373548000},"page":"103430","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["A fat chance at neuroprotection: Ketogenic diet and Parkinson's disease"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5819-4157","authenticated-orcid":false,"given":"Gazala","family":"Hitawala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Shulman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clnesp.2026.103430_bib1","year":"2025","journal-title":"Statistics"},{"key":"10.1016\/j.clnesp.2026.103430_bib2","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson's disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov Disord"},{"key":"10.1016\/j.clnesp.2026.103430_bib3","first-page":"84","article-title":"A review of ketogenic diet and lifestyle","volume":"119","author":"McGaugh","year":"2022","journal-title":"Mo Med"},{"key":"10.1016\/j.clnesp.2026.103430_bib4","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.jand.2017.06.006","article-title":"Practice paper of the academy of nutrition and dietetics: classic and modified ketogenic diets for treatment of epilepsy","volume":"117","author":"Roehl","year":"2017","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.clnesp.2026.103430_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1017\/S0954422421000214","article-title":"Ketogenic diets and the nervous system: a scoping review of neurological outcomes from nutritional ketosis in animal studies","volume":"35","author":"Field","year":"2022","journal-title":"Nutr Res Rev"},{"key":"10.1016\/j.clnesp.2026.103430_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/jnc.15341","article-title":"Systematic review \u2013 neuroprotection of ketosis in acute injury of the Mammalian central nervous system: a meta-analysis","volume":"158","author":"Gambardella","year":"2021","journal-title":"J Neurochem"},{"key":"10.1016\/j.clnesp.2026.103430_bib7","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000094170","article-title":"Induction of monocarboxylate transporter 2 expression and ketone transport following traumatic brain injury in juvenile and adult rats","volume":"28","author":"Prins","year":"2006","journal-title":"Dev Neurosci"},{"key":"10.1016\/j.clnesp.2026.103430_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0190556","article-title":"Regional cerebral effects of ketone body infusion with 3-hydroxybutyrate in humans: reduced glucose uptake, unchanged oxygen consumption and increased blood flow by positron emission tomography. A randomized, controlled trial","volume":"13","author":"Svart","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.clnesp.2026.103430_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228767","article-title":"Effects of ketone bodies on brain metabolism and function in neurodegenerative diseases","volume":"21","author":"Jensen","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnesp.2026.103430_bib10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.anpedi.2021.05.006","article-title":"Ketogenic dietary therapies for epilepsy: experience in 160 patients over 18 years","volume":"96","author":"Ruiz Herrero","year":"2022","journal-title":"An Pediatr"},{"key":"10.1016\/j.clnesp.2026.103430_bib11","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1080\/14737175.2022.2030220","article-title":"Ketogenic diet in pediatric seizures: a randomized controlled trial review and meta-analysis","volume":"22","author":"Pizzo","year":"2022","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clnesp.2026.103430_bib12","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/jnnp-2022-329074","article-title":"Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits","volume":"93","author":"Brenton","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clnesp.2026.103430_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/nu11081742","article-title":"A randomized double-blind, cross-over trial of very low-calorie diet in overweight migraine patients: a possible role for ketones?","volume":"11","author":"Di Lorenzo","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.clnesp.2026.103430_bib14","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1007\/s10072-021-05078-5","article-title":"Effectiveness of ketogenic diet in treatment of patients with refractory chronic migraine","volume":"42","author":"Bongiovanni","year":"2021","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clnesp.2026.103430_bib15","doi-asserted-by":"crossref","first-page":"6479","DOI":"10.1007\/s10072-022-06311-5","article-title":"Ketogenic diet in refractory migraine: possible efficacy and role of ketone Bodies\u2014A pilot experience","volume":"43","author":"Lovati","year":"2022","journal-title":"Neurol Sci"},{"key":"10.1016\/j.clnesp.2026.103430_bib16","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/nutrit\/nuab080","article-title":"Efficacy and tolerability of the ketogenic diet and its variations for preventing migraine in adolescents and adults: a systematic review","volume":"80","author":"Caminha","year":"2022","journal-title":"Nutr Rev"},{"key":"10.1016\/j.clnesp.2026.103430_bib17","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"J Clin Investig"},{"key":"10.1016\/j.clnesp.2026.103430_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2018.00830","article-title":"Insulin resistance in Alzheimer's disease","volume":"12","author":"Ferreira","year":"2018","journal-title":"Front Neurosci"},{"key":"10.1016\/j.clnesp.2026.103430_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189987","article-title":"Insulin and insulin resistance in Alzheimer's disease","volume":"22","author":"S\u0119dzikowska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clnesp.2026.103430_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41387-020-00142-z","article-title":"Effect of the ketogenic diet on glycemic control, insulin resistance, and lipid metabolism in patients with T2DM: a systematic review and meta-analysis","volume":"10","author":"Yuan","year":"2020","journal-title":"Nutr Diabetes"},{"key":"10.1016\/j.clnesp.2026.103430_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000515381","article-title":"European guidelines for obesity management in adults with a very low-calorie ketogenic diet: a systematic review and meta-analysis","volume":"14","author":"Muscogiuri","year":"2021","journal-title":"Obes Facts"},{"key":"10.1016\/j.clnesp.2026.103430_bib22","article-title":"Low-carbohydrate ketogenic diet for improvement of glycemic control: mechanism of action of ketosis and beneficial effects","volume":"19","author":"Sakr","year":"2023","journal-title":"Curr Diabetes Rev"},{"key":"10.1016\/j.clnesp.2026.103430_bib23","doi-asserted-by":"crossref","DOI":"10.1186\/1743-7075-2-28","article-title":"A ketogenic diet reduces amyloid beta 40 and 42 in a mouse model of Alzheimer's disease","volume":"2","author":"Van der Auwera","year":"2005","journal-title":"Nutr Metab"},{"key":"10.1016\/j.clnesp.2026.103430_bib24","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/cns.13779","article-title":"Ketogenic diet ameliorates cognitive impairment and neuroinflammation in a mouse model of Alzheimer's disease","volume":"28","author":"Xu","year":"2022","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.clnesp.2026.103430_bib25","doi-asserted-by":"crossref","DOI":"10.1186\/1743-7075-6-31","article-title":"Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial","volume":"6","author":"Henderson","year":"2009","journal-title":"Nutr Metab"},{"key":"10.1016\/j.clnesp.2026.103430_bib26","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-021-00783-x","article-title":"Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease","volume":"13","author":"Phillips","year":"2021","journal-title":"Alzheimers Res Ther"},{"key":"10.1016\/j.clnesp.2026.103430_bib27","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/S0896-6273(03)00568-3","article-title":"Parkinson's disease: mechanisms and models","volume":"39","author":"Dauer","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.clnesp.2026.103430_bib28","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1126\/science.290.5493.985","article-title":"Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions","volume":"290","author":"Giasson","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.clnesp.2026.103430_bib29","doi-asserted-by":"crossref","first-page":"45996","DOI":"10.1074\/jbc.M106777200","article-title":"Residual structure and dynamics in Parkinson's disease-associated mutants of alpha-synuclein","volume":"276","author":"Bussell","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clnesp.2026.103430_bib30","series-title":"Free radicals in brain pathophysiology","article-title":"ROS and Parkinson's disease: a view to a kill","author":"Przedborski","year":"2000"},{"key":"10.1016\/j.clnesp.2026.103430_bib31","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1097\/00019052-200108000-00008","article-title":"Parkin and Parkinson's disease","volume":"14","author":"Mizuno","year":"2001","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.clnesp.2026.103430_bib32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0896-6273(01)00177-5","article-title":"Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases","volume":"29","author":"Sherman","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.clnesp.2026.103430_bib33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1126\/science.1060627","article-title":"Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease","volume":"293","author":"Shimura","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.clnesp.2026.103430_bib34","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1093\/hmg\/10.9.919","article-title":"Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis","volume":"10","author":"Tanaka","year":"2001","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.clnesp.2026.103430_bib35","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0896-6273(02)01125-X","article-title":"Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons","volume":"36","author":"Petrucelli","year":"2002","journal-title":"Neuron"},{"key":"10.1016\/j.clnesp.2026.103430_bib36","doi-asserted-by":"crossref","DOI":"10.3390\/cells12030486","article-title":"Effect of the ketone body, D-\u03b2-hydroxybutyrate, on sirtuin2-mediated regulation of mitochondrial quality control and the autophagy-lysosomal pathway","volume":"12","author":"G\u00f3mora-Garc\u00eda","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.clnesp.2026.103430_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106469","article-title":"A unifying mechanism of ketogenic diet action: the multiple roles of nicotinamide adenine dinucleotide","volume":"167","author":"Elamin","year":"2020","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clnesp.2026.103430_bib38","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.neuroscience.2006.11.065","article-title":"Ketones inhibit mitochondrial production of reactive oxygen species production following glutamate excitotoxicity by increasing NADH oxidation","volume":"145","author":"Maalouf","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.clnesp.2026.103430_bib39","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/jnc.13868","article-title":"3-Hydroxybutyrate regulates energy metabolism and induces BDNF expression in cerebral cortical neurons","volume":"139","author":"Marosi","year":"2016","journal-title":"J Neurochem"},{"key":"10.1016\/j.clnesp.2026.103430_bib40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/15216540152845939","article-title":"Complex I and Parkinson's disease","volume":"52","author":"Greenamyre","year":"2001","journal-title":"IUBMB Life"},{"key":"10.1016\/j.clnesp.2026.103430_bib41","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1471-4159.1990.tb02325.x","article-title":"Mitochondrial complex I deficiency in Parkinson's disease","volume":"54","author":"Schapira","year":"1990","journal-title":"J Neurochem"},{"key":"10.1016\/j.clnesp.2026.103430_bib42","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ana.410260606","article-title":"Abnormalities of the electron transport chain in idiopathic Parkinson's disease","volume":"26","author":"Parker","year":"1989","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clnesp.2026.103430_bib43","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/ana.410400417","article-title":"Origin and functional consequences of the complex I defect in Parkinson's disease","volume":"40","author":"Swerdlow","year":"1996","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clnesp.2026.103430_bib44","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1073\/pnas.82.7.2173","article-title":"Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 -tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity","volume":"82","author":"Javitch","year":"1985","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clnesp.2026.103430_bib45","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1471-4159.1986.tb00722.x","article-title":"Prevention of the nigrostriatal toxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by inhibitors of 3,4-dihydroxyphenylethylamine transport","volume":"47","author":"Mayer","year":"1986","journal-title":"J Neurochem"},{"key":"10.1016\/j.clnesp.2026.103430_bib46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1471-4159.1991.tb02134.x","article-title":"Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain","volume":"57","author":"Chan","year":"1991","journal-title":"J Neurochem"},{"key":"10.1016\/j.clnesp.2026.103430_bib47","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF03655585","article-title":"Effect of MPTP on brain mitochondrial H2O2 and ATP production and on dopamine and DOPAC in the striatum","volume":"55","author":"Fabre","year":"1999","journal-title":"J Physiol Biochem"},{"key":"10.1016\/j.clnesp.2026.103430_bib48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1749-6632.2003.tb07476.x","article-title":"The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model: a tool to explore the pathogenesis of Parkinson's disease","volume":"991","author":"Przedborski","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clnesp.2026.103430_bib49","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1523\/JNEUROSCI.12-05-01658.1992","article-title":"Transgenic mice with increased Cu\/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity","volume":"12","author":"Przedborski","year":"1992","journal-title":"J Neurosci"},{"key":"10.1016\/j.clnesp.2026.103430_bib50","doi-asserted-by":"crossref","first-page":"5256","DOI":"10.1523\/JNEUROSCI.0984-06.2006","article-title":"Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled","volume":"26","author":"Keeney","year":"2006","journal-title":"J Neurosci"},{"key":"10.1016\/j.clnesp.2026.103430_bib51","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1212\/WNL.50.3.793","article-title":"Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients","volume":"50","author":"Shults","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.clnesp.2026.103430_bib52","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1172\/JCI200318797","article-title":"D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease","volume":"112","author":"Tieu","year":"2003","journal-title":"J Clin Investig"},{"key":"10.1016\/j.clnesp.2026.103430_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.brainres.2009.06.060","article-title":"Ketogenic diet protects dopaminergic neurons against 6-OHDA neurotoxicity via up-regulating glutathione in a rat model of Parkinson's disease","volume":"1286","author":"Cheng","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.clnesp.2026.103430_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577543","article-title":"A selective NLRP3 inflammasome inhibitor attenuates behavioral deficits and neuroinflammation in a mouse model of Parkinson's disease","volume":"354","author":"Huang","year":"2021","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.clnesp.2026.103430_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2024.149129","article-title":"A novel selective NLRP3 inhibitor shows disease-modifying potential in animal models of Parkinson's disease","volume":"1842","author":"Chatterjee","year":"2024","journal-title":"Brain Res"},{"key":"10.1016\/j.clnesp.2026.103430_bib56","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm.3804","article-title":"The ketone metabolite \u03b2-hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease","volume":"21","author":"Youm","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.clnesp.2026.103430_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms4944","article-title":"The \u03b2-hydroxybutyrate receptor HCA2 activates a neuroprotective subset of macrophages","volume":"5","author":"Rahman","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.clnesp.2026.103430_bib58","doi-asserted-by":"crossref","DOI":"10.1186\/s12576-020-00786-7","article-title":"The effect of ketogenic diets on neurogenesis and apoptosis in the dentate gyrus of the male rat hippocampus","volume":"71","author":"Irfannuddin","year":"2021","journal-title":"J Physiol Sci"},{"key":"10.1016\/j.clnesp.2026.103430_bib59","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12031-010-9336-y","article-title":"Neuroprotective and anti-inflammatory activities of ketogenic diet on MPTP-induced neurotoxicity","volume":"42","author":"Yang","year":"2010","journal-title":"J Mol Neurosci"},{"key":"10.1016\/j.clnesp.2026.103430_bib60","first-page":"63","article-title":"The efficacy of the ketogenic diet on motor functions in Parkinson's disease: a rat model","volume":"15","author":"Shaafi","year":"2016","journal-title":"Iran J Neurol"},{"key":"10.1016\/j.clnesp.2026.103430_bib61","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/mds.26942","article-title":"Parkinson's disease and Parkinson's disease medications have distinct signatures of the gut microbiome","volume":"32","author":"Hill-Burns","year":"2017","journal-title":"Mov Disord"},{"key":"10.1016\/j.clnesp.2026.103430_bib62","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/mds.27581","article-title":"Unraveling gut microbiota in Parkinson's disease and atypical parkinsonism","volume":"34","author":"Barichella","year":"2019","journal-title":"Mov Disord"},{"key":"10.1016\/j.clnesp.2026.103430_bib63","article-title":"Longitudinal analysis of fecal microbiome and pathologic processes in a rotenone induced mice model of Parkinson's disease","volume":"9","author":"Yang","year":"2017","journal-title":"Front Aging Neurosci"},{"key":"10.1016\/j.clnesp.2026.103430_bib64","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.neuro.2019.09.004","article-title":"MitoPark transgenic mouse model recapitulates the gastrointestinal dysfunction and gut-microbiome changes of Parkinson's disease","volume":"75","author":"Ghaisas","year":"2019","journal-title":"Neurotoxicology"},{"issue":"Suppl 2","key":"10.1016\/j.clnesp.2026.103430_bib65","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000518147","article-title":"Parkinson's disease and gut microbiota","volume":"77","author":"Hirayama","year":"2021","journal-title":"Ann Nutr Metab"},{"key":"10.1016\/j.clnesp.2026.103430_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/cells11060978","article-title":"Hydrogen sulfide produced by gut bacteria may induce Parkinson's disease","volume":"11","author":"Murros","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.clnesp.2026.103430_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.652617","article-title":"Desulfovibrio bacteria are associated with Parkinson's disease","volume":"11","author":"Murros","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.clnesp.2026.103430_bib68","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10020436","article-title":"Role of microbiota-gut-brain axis in regulating dopaminergic signaling","volume":"10","author":"Hamamah","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.clnesp.2026.103430_bib69","article-title":"Ketogenic diet protects MPTP-induced mouse model of Parkinson's disease via altering gut microbiota and metabolites","volume":"e268","author":"Jiang","year":"2023","journal-title":"MedComm"},{"key":"10.1016\/j.clnesp.2026.103430_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2020.584130","article-title":"A ketone ester drink enhances endurance exercise performance in Parkinson's disease","volume":"14","author":"Norwitz","year":"2020","journal-title":"Front Neurosci"},{"key":"10.1016\/j.clnesp.2026.103430_bib71","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-024-03603-5","article-title":"A randomized feasibility trial of medium chain triglyceride-supplemented ketogenic diet in people with Parkinson's disease","volume":"24","author":"Choi","year":"2024","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clnesp.2026.103430_bib72","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/mds.27390","article-title":"Low-fat versus ketogenic diet in Parkinson's disease: a pilot randomized controlled trial","volume":"33","author":"Phillips","year":"2018","journal-title":"Mov Disord"},{"key":"10.1016\/j.clnesp.2026.103430_bib73","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1212\/01.WNL.0000152046.11390.45","article-title":"Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study","volume":"64","author":"Vanitallie","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.clnesp.2026.103430_bib74","first-page":"41","article-title":"Nutritional ketosis for mild cognitive impairment in Parkinson's disease: a controlled pilot trial","volume":"1","author":"Krikorian","year":"2019","journal-title":"Clin Park Relat Disord"},{"key":"10.1016\/j.clnesp.2026.103430_bib75","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.23684","article-title":"Effects of a ketogenic diet on symptoms, biomarkers, depression, and anxiety in Parkinson's disease: a case study","author":"Tidman","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.clnesp.2026.103430_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2025.1601446","article-title":"A mixed methods feasibility study of a ketogenic diet as treatment for Parkinson's disease","volume":"12","author":"Worster","year":"2025","journal-title":"Front Nutr"},{"key":"10.1016\/j.clnesp.2026.103430_bib77","doi-asserted-by":"crossref","DOI":"10.3390\/nu13030814","article-title":"A ketogenic low-carbohydrate high-fat diet increases LDL cholesterol in healthy, young, normal-weight women: a randomized controlled feeding trial","volume":"13","author":"Bur\u00e9n","year":"2021","journal-title":"Nutrients"},{"key":"10.1016\/j.clnesp.2026.103430_bib78","doi-asserted-by":"crossref","DOI":"10.1016\/j.eprac.2026.01.009","article-title":"The impact of the ketogenic diet on the lipid profile in adults: a comprehensive review and meta-regression analysis of randomized controlled trials","author":"Chang","year":"2026","journal-title":"Endocr Pract"},{"key":"10.1016\/j.clnesp.2026.103430_bib79","article-title":"Assessment of micronutrients in a 12-wk ketogenic diet in obese adults","volume":"67\u201368","author":"Kenig","year":"2019","journal-title":"Nutrition"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726005279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726005279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:24:36Z","timestamp":1790018676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457726005279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":79,"alternative-id":["S2405457726005279"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.103430","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A fat chance at neuroprotection: Ketogenic diet and Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.103430","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of European Society for Clinical Nutrition and Metabolism.","name":"copyright","label":"Copyright"}],"article-number":"103430"}}